MediGene and The Johns Hopkins University Sign Development Collaboration for First Vaccine Candidates from MediGene's AAVLP Platform
08:35 31.05.11
MediGene AG /
MediGene and The Johns Hopkins University Sign Development Collaboration for
First Vaccine Candidates from MediGene's AAVLP Platform
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Examination of product candidates for the prevention of HPV-associated diseases
Martinsried/Munich, May 31, 2011. The biotech company MediGene AG (Frankfurt,
Prime Standard) and The Johns Hopkins University, Baltimore, USA, have agreed to
collaborate in the field of AAVLP vaccine technology. The objective of this
collaboration is to test vaccine candidates derived from the AAVLP program for
the prevention of HPV-associated cancer types, and in so doing to further
advance the development of the AAVLP program. The vaccine candidates examined
within the framework of this collaboration target at a number of carcinogenic
human papillomaviruses (HPV) causing, for example, cervical cancer. The lead
investigator will be Richard B. S. Roden, Ph.D., professor of
Gynecology/Obstetrics and Oncology at Johns Hopkins University School of
Medicine, one of the world's leading scientists in the field of HPV research.
Dr. Frank Mathias, CEO of MediGene AG, commented: "The cooperation with this
internationally renowned and outstanding research institution is the first
significant step in the advancement of our innovative AAVLP vaccine program. The
acknowledged expertise of Dr Roden and his team will be invaluable in the
testing of the first AAVLP vaccine candidates in an indication of high medical
need."
AAVLP: In its AAVLP program, which is currently at the pre-clinical stage,
MediGene is investigating the use of adeno-associated viruses (AAV) as a
vaccine. The adeno-associated virus is non-pathogenic, i.e. it does not cause
disease. The virus protein shell, the capsid, is suited for the production of
so-called virus-like particles (VLP), which can be used as a basis for novel
vaccines.
By inserting short antigenic peptides (B-cell epitopes) into the AAV capsid, a
highly specific antibody reaction against selected target molecules can be
induced in the body. These antibodies can protect the body (i.e. have a
prophylactic effect) or act as a therapy against existing diseases.
MediGene is currently conducting research into the application of AAVLP
technology for the treatment of cancer and viral infections, and is examining
the possibility of using AAV libraries for the systematic identification of
suitable vaccine candidates. The key benefit of this technology may be the
possibility of transferring the efficacy of existing therapeutic antibodies
directly into a vaccine.
In preclinical studies, AAVLP-based vaccines have shown an excellent safety
profile. Therefore they may not only constitute an interesting alternative to
conventional vaccines, but also significantly widen the range of applications
for vaccines against cancer and other diseases.
MediGene holds an extensive IP portfolio regarding the AAVLP technology.
HPV:The term "human papillomaviruses" describes a family of viruses that is
capable of infecting the epithelium of the skin or different mucous membranes,
causing tumor-like growth. The viruses are typically transmitted through sexual
contact. Depending on the HPV type, the consequences of an infection vary in
their severity. Some particularly aggressive types of HPV are capable of causing
malignant changes, e.g. cervical cancer in women.
Cervical cancer: Cervical carcinoma is the second most common cancer in women,
in most cases caused by "high risk" types HPV 16, 18, 31, and 45. Despite
extensive screening programs, the worldwide incidence is more than 450,000 new
cases annually, with 350,000 deaths annually. About 1-4% of the female
population show high-grade cervical dysplasia.
This press release contains forward-looking statements representing the opinion
of MediGene as of the date of this release. The actual results achieved by
MediGene may differ significantly from the forward-looking statements made
herein. MediGene is not bound to update any of these forward-looking statements.
MediGene(®) is a registered trademarks of MediGene AG. These trademarks may be
owned or licensed in select locations only.
- ends -
MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology
company headquartered in Martinsried/Munich, Germany. MediGene is the first
German biotech company to have revenues from marketed products. It has various
drug candidates in clinical development and possesses innovative platform
technologies. MediGene focuses on clinical research and development of novel
drugs against cancer and autoimmune diseases.
Contact MediGene AG
Julia Hofmann, Kerstin Langlotz
Investor & Public Relations
Tel.: +49 - 89 - 85 65 - 33 01
Fax: +49 - 89 - 85 65 - 29 20
Email: investor@medigene.com
--- End of Message ---
|
1 |
... |
84 |
85 |
86 |
|
88 |
89 |
90 |
...
| 801
Thread abonnieren
